Observational studyAdvances in therapy2026

Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.

Giuseppe Privitera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.